Skip to content
About
Oncolytic Viruses
Immunotherapy Combinations
R&D Facility
Team
Company News
Corporate Investor Deck
Leadership Team
Board
Management Team
Our Technology
IVX037
IVX055
Pipeline
Scientific Presentations
Pre-clinical / discovery
Clinical
Therapeutic Strategy
Innovent Collaboration
Pipeline
Investor Centre
Corporate Deck
Company Announcements
In the News
ESG
Recruitment
Contact
Menu
About
Oncolytic Viruses
Immunotherapy Combinations
R&D Facility
Team
Company News
Corporate Investor Deck
Leadership Team
Board
Management Team
Our Technology
IVX037
IVX055
Pipeline
Scientific Presentations
Pre-clinical / discovery
Clinical
Therapeutic Strategy
Innovent Collaboration
Pipeline
Investor Centre
Corporate Deck
Company Announcements
In the News
ESG
Recruitment
Contact
News
June 5, 2023
OneVentures backs cancer biotech ImmVirX in $25 million Series B
You can read the full story
here
.
Prev
Previous
Next
Next